Skip to main content

Advertisement

Table 3 Treatment duration and reason for final cessation of everolimus treatment in the RCC group

From: Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function

  AKI group Non-AKI group P-value
Treatment duration (weeks) 18 (9, 35) 20 (12, 36) NS
Total dose (mg) 1050 (615, 1913) 1173 (683, 1915) NS
Discontinuation of drug 15 (71%) 53 (74%) NS
Reason for discontinuation    NS
 Disease progression 10 (67%) 35 (66%)  
 Adverse effect 2 (13%) 9 (17%)  
 Self-withdrawal 3 (20%) 9 (17%)  
  1. RCC, renal cell carcinoma; AKI, acute kidney injury; NS, not significant.